title: [Effect of Cilazapril on endothelial cell function and fibrinolysis system in the canine atrial fibrillation models].
abstract: OBJECTIVE
  To investigate the effect of cilazapril on endothelial cell function and fibrinolysis system in the canine atrial fibrillation (AF) models.
  
  
  METHODS
  All canines were divided into three groups: (1) Control group, without atrial pacing; (2) Atrial pacing group, in which atrial fibrillation was established by rapid atrial pacing at 400 bpm for 6 weeks; (3) Atrial pacing together with cilazapril group, in which cilazapril was given before and after atrial pacing. Nitric oxide (NO) of atrial endocardium was measured with NO-specific microelectrode. The expression of plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (tPA) protein in atrium was determined by Western Blot analysis and immunohistochemical staining. Plasma levels of von Willebrand Factor (vWF), PAI-1 and tPA were analyzed by enzyme-linked immunoadsorbent assay.
  
  
  RESULTS
  NO production from atrial endocardium was significantly increased in atrial pacing together with cilazapril group than atrial pacing group [(42.6 +/- 9.9) nmol/L vs (23.4 +/- 5.8) nmol/L, P < 0.05], whereas the plasma levels of vWF were decreased [(75.4 +/- 12.8)% vs (125.9 +/- 20.6)%, P < 0.05]. Compared to controls, the expression of atrium tPA protein in atrial pacing together with cilazapril group was significantly upregulated (4052 +/- 857 vs 1936 +/- 421, P < 0.05) and PAI-1 protein was downregulated (2487 +/- 542 vs 3164 +/- 827, P < 0.05). Cilazapril also significantly increased tPA antigen and decreased PAI-1 antigen in plasma.
  
  
  CONCLUSIONS
  Cilazapril can favorably improve endothelial function and resume the balance of fibrinolysis system in AF, which might be of beneficial to hypercoagulated state in AF.
authors.affiliation: Department of Cardiology, First Clinical College of Harbin Medical University, Harbin 150001, China.
authors.forename: Wei-min
authors.initials: WM
authors.lastname: Li
authors.forename: Wei
authors.initials: W
authors.lastname: Han
authors.forename: Zi-jun
authors.initials: ZJ
authors.lastname: Liang
authors.forename: Dong-lai
authors.initials: DL
authors.lastname: Wu
authors.forename: Yong-lin
authors.initials: YL
authors.lastname: Huang
authors.forename: Shang-jin
authors.initials: SJ
authors.lastname: Cui
authors.forename: Yue
authors.initials: Y
authors.lastname: Li
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D001281:Atrial Fibrillation / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D017315:Cilazapril / Q000494:pharmacology*; D004195:Disease Models, Animal; D004285:Dogs; D042783:Endothelial Cells / Q000187:drug effects* / Q000502:physiology; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D007150:Immunohistochemistry; D008297:Male; D017395:Plasminogen Activator Inhibitor 1 / Q000032:analysis; D010959:Tissue Plasminogen Activator / Q000032:analysis
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D017395:Plasminogen Activator Inhibitor 1; D017315:Cilazapril; D010959:Tissue Plasminogen Activator